Evidence map›Paper›PMID 26034980›Full record

ArticleOncology reports2015

Selective enhancement of hypoxic cell killing by tempol-regulated suicide gene expression.

Go Kagiya, Ryohei Ogawa, Rajani Choudhuri, John A Cook, Masanori Hatashita, Yoshikazu Tanaka, Kana Koda, Kei Yamashita, Makoto Kubo, Fumitaka Kawakami and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Oncology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Go KagiyaSchool of Allied Health Sciences, Kitasato University, Minami-ku, Sagamihara, Kanagawa 228-8555, Japan.
Ryohei OgawaDepartment of Radiological Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
Rajani ChoudhuriRadiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
John A CookRadiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Masanori HatashitaBiology Group, The Wakasa Wan Energy Research Center, Tsuruga, Fukui 914-0192, Japan.
Yoshikazu TanakaBiology Group, The Wakasa Wan Energy Research Center, Tsuruga, Fukui 914-0192, Japan.
Kana KodaRadiation Oncol-ogy, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ward, Tokyo 135-8550, Japan.
Kei YamashitaGraduate School of Medical and Pharmaceutical Sciences, Chiba University, Inage-ku, Chiba 236-8555, Japan.
Makoto KuboSchool of Allied Health Sciences, Kitasato University, Minami-ku, Sagamihara, Kanagawa 228-8555, Japan.
Fumitaka KawakamiSchool of Allied Health Sciences, Kitasato University, Minami-ku, Sagamihara, Kanagawa 228-8555, Japan.
James B MitchellRadiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Kitasato University · JPFoundation Wakasa Wan Energy Research Center · JPNational Cancer Institute · USChiba University · JPNational Institutes of Health · USUniversity of Toyama · JP

Funding

Nitroxides as Protectors Against Oxidative StressZIASC006387 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI MITCHELL, JAMES · 2009 to 2025
$6.9M
Intramural NIH HHS
6 · The paper itself

Abstract

The presence of hypoxic regions within solid tumors is caused by an imbalance between cell proliferation and angiogenesis. Such regions may facilitate the onset of recurrence after radiation therapy and chemotherapy, as hypoxic cells show resistance to these treatments. We found that tempol, a nitroxide, strongly induces the accumulation of hypoxia-inducible factor (HIF)-1α, particularly under conditions of hypoxia. We, therefore, evaluated whether tempol enhances the gene expression via HIF-1α, potentially leading to various applications for cancer gene therapy targeting hypoxic cells. Consequently, following treatment with tempol under hypoxia, the luciferase (Luc) activity in the cells transfected with the plasmid containing the luc gene with the oxygen-dependent degradation domain and a promoter composed of hypoxia-responsive elements increased up to approximately 10-fold compared to that observed in cells treated identically with the exception of tempol. The plasmid constructed by replacing the luc gene with the fcy::fur fusion gene as a suicide gene, strongly induced the accumulation of the Fcy::Fur fusion protein, only when incubated in the presence of the hypoxic mimic CoCl2 and tempol. The transfected cells were successfully killed with the addition of 5-fluorocytosine to the cell culture according to the fcy::fur fusion gene expression. As similar but lesser enhancement of the Luc activity was also observed in solid tumor tissues in nude mice, this strategy may be applied for hypoxic cancer eradication.

Indexed as

Genes, Transgenic, SuicideAnimalsBreast NeoplasmsCell HypoxiaCell Line, TumorCyclic N-OxidesFemaleHumansHypoxia-Inducible Factor 1, alpha SubunitLuciferasesMCF-7 CellsMiceRecombinant ProteinsSpin LabelsCyclic N-OxidesHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitLuciferasesRecombinant ProteinsSpin Labelstempol

Identifiers

PMID26034980
PMCPMC4487668
OpenAlexW1601855728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.